{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:47:05Z","timestamp":1774745225737,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["99110141570"],"award-info":[{"award-number":["99110141570"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["65956"],"award-info":[{"award-number":["65956"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.intimp.2023.110806","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T09:55:11Z","timestamp":1692266111000},"page":"110806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Therapeutic potential of infliximab for pruritus in mice model of cholestasis induced by bile duct ligation: Possible involvement of IL-31"],"prefix":"10.1016","volume":"123","author":[{"given":"Zahra","family":"Ebrahim Soltani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadmahdi","family":"Khavandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazgol-Sadat","family":"Haddadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Shayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Khalilzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Reza","family":"Dehpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2023.110806_b0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.7861\/clinmedicine.15-4-351","article-title":"Drug treatment of pruritus in liver diseases","volume":"15","author":"Hegade","year":"2015","journal-title":"Clin. Med. (Lond.)"},{"issue":"8 Suppl","key":"10.1016\/j.intimp.2023.110806_b0010","first-page":"72s","article-title":"The production of tumor necrosis factor-alpha by macrophages in rats with acute alcohol loading","volume":"27","author":"Kitazawa","year":"2003","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.intimp.2023.110806_b0015","first-page":"110","article-title":"Serum levels of tumor necrosis factor-alpha correlate with severity of hepatic encephalopathy due to chronic liver failure","volume":"24","author":"Odeh","year":"2004","journal-title":"Liver international, official journal of the International Association for the Study of the Liver."},{"issue":"2","key":"10.1016\/j.intimp.2023.110806_b0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4103\/1110-2098.163913","article-title":"Study of serum tumor necrosis factor-alpha in patients with liver cirrhosis","volume":"28","author":"Sabry","year":"2015","journal-title":"Menoufia Medical Journal."},{"issue":"3","key":"10.1016\/j.intimp.2023.110806_b0025","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbrc.2008.10.155","article-title":"TNFalpha is required for cholestasis-induced liver fibrosis in the mouse","volume":"378","author":"G\u00e4bele","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2023.110806_b0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12264-017-0124-3","article-title":"TNF-\u03b1\/TNFR1 Signaling is Required for the Full Expression of Acute and Chronic Itch in Mice via Peripheral and Central Mechanisms","volume":"34","author":"Miao","year":"2018","journal-title":"Neurosci. Bull."},{"issue":"11","key":"10.1016\/j.intimp.2023.110806_b0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1155\/2012\/623862","article-title":"Blood cytokine, chemokine and gene expression in cholestasis patients with intractable pruritis treated with a molecular adsorbent recirculating system, a case series","volume":"26","author":"Lisboa","year":"2012","journal-title":"Canadian journal of gastroenterology = Journal canadien de gastroenterologie."},{"issue":"5","key":"10.1016\/j.intimp.2023.110806_b0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1744-9987.2009.00759.x","article-title":"Predictive criteria for the outcome of patients with acute liver failure treated with the albumin dialysis molecular adsorbent recirculating system","volume":"13","author":"Novelli","year":"2009","journal-title":"Therapeutic apheresis and dialysis, official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy."},{"issue":"4","key":"10.1016\/j.intimp.2023.110806_b0045","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.transproceed.2009.03.035","article-title":"Cytokine level modifications, molecular adsorbent recirculating system versus standard medical therapy","volume":"41","author":"Novelli","year":"2009","journal-title":"Transpl. Proc."},{"issue":"6","key":"10.1016\/j.intimp.2023.110806_b0050","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.transproceed.2005.06.040","article-title":"The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure","volume":"37","author":"Di Campli","year":"2005","journal-title":"Transpl. Proc."},{"issue":"1","key":"10.1016\/j.intimp.2023.110806_b0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/j.1536-4801.2005.tb00926.x","article-title":"Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children","volume":"40","author":"Auth","year":"2005","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2023.110806_b0060","first-page":"7","article-title":"Cytokines and liver failure, modification of TNF- and IL-6 in patients with acute on chronic liver decompensation treated with Molecular Adsorbent Recycling System (MARS)","volume":"74","author":"Ambrosino","year":"2003","journal-title":"Acta bio-medica, Atenei Parmensis."},{"issue":"3","key":"10.1016\/j.intimp.2023.110806_b0065","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.smim.2014.05.004","article-title":"Regulation of NF-\u03baB by TNF family cytokines","volume":"26","author":"Hayden","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2023.110806_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a Clinical Target for Pruritus Treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front. Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.110806_b0075","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.110806_b0080","doi-asserted-by":"crossref","unstructured":"M. Feld, R. Garcia, J. Buddenkotte, S. Katayama, K. Lewis, G. Muirhead, et al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J. Allergy Clin. Immunol. 2016;138(2):500-8.e24.","DOI":"10.1016\/j.jaci.2016.02.020"},{"key":"10.1016\/j.intimp.2023.110806_b0085","unstructured":"J. Xu, Y. Wang, M. Khoshdeli, M. Peach, J.-C. Chuang, J. Lin, et al. IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Hepatology. n\/a(n\/a)."},{"issue":"8","key":"10.1016\/j.intimp.2023.110806_b0090","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2023.110806_b0095","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2147\/DDDT.S200147","article-title":"Infliximab and biosimilar infliximab in psoriasis, efficacy, loss of efficacy, and adverse events","volume":"13","author":"Subedi","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2023.110806_b0100","first-page":"146","article-title":"Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis, a systematic review and meta-analysis","volume":"55","author":"Costa Jde","year":"2015","journal-title":"Rev. Bras. Reumatol."},{"issue":"43","key":"10.1016\/j.intimp.2023.110806_b0105","doi-asserted-by":"crossref","first-page":"6843","DOI":"10.3748\/wjg.v11.i43.6843","article-title":"Favorable response to subcutaneous administration of infliximab in rats with experimental colitis","volume":"11","author":"Triantafillidis","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2023.110806_b0110","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/295891","article-title":"Management of pruritus in chronic liver disease","volume":"2015","author":"Bhalerao","year":"2015","journal-title":"Dermatol. Res. Pract."},{"issue":"3","key":"10.1016\/j.intimp.2023.110806_b0115","first-page":"E252","article-title":"Prevalence of pruritus in patients with chronic liver disease","volume":"48","author":"Oeda","year":"2018","journal-title":"A multicenter study. Hepatol Res."},{"issue":"4","key":"10.1016\/j.intimp.2023.110806_b0120","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/toxres\/tfab073","article-title":"The activation of nuclear factor-E2-related factor 2 (Nrf2)\/heme oxygenase-1 (HO-1) signaling blunts cholestasis-induced liver and kidney injury","volume":"10","author":"Mousavi","year":"2021","journal-title":"Toxicol. Res."},{"issue":"4","key":"10.1016\/j.intimp.2023.110806_b0125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5114\/ceh.2021.111014","article-title":"Pentoxifylline mitigates cholestasis-related cholemic nephropathy","volume":"7","author":"Mehdi Ommati","year":"2021","journal-title":"Clinical and Experimental Hepatology."},{"issue":"4","key":"10.1016\/j.intimp.2023.110806_b0130","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000530307","article-title":"Cholestasis-Associated Pulmonary Inflammation, Oxidative Stress, and Tissue Fibrosis, The Protective Role of the Biogenic Amine Agmatine","volume":"108","author":"Ommati","year":"2023","journal-title":"Pharmacology"},{"issue":"1","key":"10.1016\/j.intimp.2023.110806_b0135","doi-asserted-by":"crossref","first-page":"17558","DOI":"10.1038\/s41598-022-22423-6","article-title":"A mouse model of hepatic encephalopathy, bile duct ligation induces brain ammonia overload, glial cell activation and neuroinflammation","volume":"12","author":"Claeys","year":"2022","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2023.110806_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041974","article-title":"Electroacupuncture at Neurogenic Spots in Referred Pain Areas Attenuates Hepatic Damages in Bile Duct-Ligated Rats","volume":"22","author":"Yi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2023.110806_b0145","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00210-020-02040-8","article-title":"Silymarin mitigates bile duct obstruction-induced cholemic nephropathy","volume":"394","author":"Ommati","year":"2021","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2023.110806_b0150","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00210-022-02291-7","article-title":"Taurine mitigates the development of pulmonary inflammation, oxidative stress, and histopathological alterations in a rat model of bile duct ligation","volume":"395","author":"Ommati","year":"2022","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2023.110806_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071485","article-title":"Inflammatory and Noninflammatory Itch, Implications in Pathophysiology-Directed Treatments","volume":"18","author":"Wong","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2023.110806_b0160","doi-asserted-by":"crossref","first-page":"e12344","DOI":"10.1016\/j.heliyon.2022.e12344","article-title":"Fluvoxamine ameliorates oxidative stress and inflammation induced by bile-duct ligation in male rats","volume":"8","author":"Barmoudeh","year":"2022","journal-title":"Heliyon."},{"issue":"2","key":"10.1016\/j.intimp.2023.110806_b0165","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11064-014-1330-2","article-title":"Rats with mild bile duct ligation show hepatic encephalopathy with cognitive and motor impairment in the absence of cirrhosis, effects of alcohol ingestion","volume":"40","author":"Gim\u00e9nez-Garz\u00f3","year":"2015","journal-title":"Neurochem. Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.110806_b0170","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1499-3872(16)60164-9","article-title":"Quercetin protects liver injury induced by bile duct ligation via attenuation of Rac1 and NADPH oxidase1 expression in rats","volume":"16","author":"Kabirifar","year":"2017","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"6","key":"10.1016\/j.intimp.2023.110806_b0175","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chom.2016.05.010","article-title":"Pain and Itch, Beneficial or Harmful to Antimicrobial Defense?","volume":"19","author":"Baral","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.intimp.2023.110806_b0180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1744-8069-4-29","article-title":"Histamine-induced itch and its relationship with pain","volume":"4","author":"Shim","year":"2008","journal-title":"Mol. Pain"},{"issue":"2","key":"10.1016\/j.intimp.2023.110806_b0185","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12264-012-1202-1","article-title":"Peripheral mechanisms of itch","volume":"28","author":"McNeil","year":"2012","journal-title":"Neurosci. Bull."},{"issue":"10","key":"10.1016\/j.intimp.2023.110806_b0190","first-page":"1404","article-title":"Management of the pruritus of cholestasis, potential role of opiate antagonists","volume":"86","author":"Bergasa","year":"1991","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110806_b0195","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40261-022-01162-6","article-title":"Re-Routing Infliximab Therapy, Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit","volume":"42","author":"Alten","year":"2022","journal-title":"Clin. Drug Invest."},{"issue":"9","key":"10.1016\/j.intimp.2023.110806_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092130","article-title":"Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study","volume":"10","author":"Huguet","year":"2022","journal-title":"Biomedicines."},{"issue":"20","key":"10.1016\/j.intimp.2023.110806_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11206173","article-title":"Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics","volume":"11","author":"Little","year":"2022","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.110806_b0210","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized Controlled Trial, Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.intimp.2023.110806_b0215","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13], A Multicentre Cohort Study","volume":"16","author":"Smith","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.intimp.2023.110806_b0220","doi-asserted-by":"crossref","unstructured":"Kapila N, Gonzalez A, Rosado JM, Flocco G, Salomon F, Abusaif M, et al. Safety of anti-TNF agents in patients with compensated cirrhosis, a case-control study. Therap Adv Gastroenterol. 2021;14:17562848211037094.","DOI":"10.1177\/17562848211037094"},{"key":"10.1016\/j.intimp.2023.110806_b0225","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/581631","article-title":"Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease, a recent update","volume":"2013","author":"Guo","year":"2013","journal-title":"Biomed Res. Int."},{"issue":"11","key":"10.1016\/j.intimp.2023.110806_b0230","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jid.2019.04.017","article-title":"Role of SNAREs in Atopic Dermatitis-Related Cytokine Secretion and Skin-Nerve Communication","volume":"139","author":"Meng","year":"2019","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.intimp.2023.110806_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102000","article-title":"Myricetin inhibits TNF-\u03b1-induced inflammation in A549 cells via the SIRT1\/NF-\u03baB pathway","volume":"65","author":"Chen","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2023.110806_b0240","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/JLB.2MR0120-510R","article-title":"Distinct modes of TNF signaling through its two receptors in health and disease","volume":"107","author":"Atretkhany","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2023.110806_b0245","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.toxlet.2021.05.012","article-title":"The inhibition of NF\u043aB signaling and inflammatory response as a strategy for blunting bile acid-induced hepatic and renal toxicity","volume":"349","author":"Ahmadi","year":"2021","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.intimp.2023.110806_b0250","doi-asserted-by":"crossref","unstructured":"J. Meng, M. Moriyama, M. Feld, J. Buddenkotte, T. Buhl, A. Sz\u00f6ll\u00f6si, et al. New mechanism underlying IL-31-induced atopic dermatitis. J. Allergy Clin. Immunol. 2018;141(5):1677-89.e8.","DOI":"10.1016\/j.jaci.2017.12.1002"},{"issue":"7","key":"10.1016\/j.intimp.2023.110806_b0255","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/09546634.2017.1290205","article-title":"Interleukin-31 pathway and its role in atopic dermatitis, a systematic review","volume":"28","author":"Saleem","year":"2017","journal-title":"J. Dermatolog. Treat."},{"issue":"1","key":"10.1016\/j.intimp.2023.110806_b0260","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-2094-7-16","article-title":"Mechanisms of tumor necrosis factor-\u03b1-induced interleukin-6 synthesis in glioma cells","volume":"7","author":"Tanabe","year":"2010","journal-title":"J. Neuroinflammation"},{"issue":"13","key":"10.1016\/j.intimp.2023.110806_b0265","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1074\/jbc.273.13.7566","article-title":"Tumor necrosis factor-alpha induces interleukin-6 production and integrin ligand expression by distinct transduction pathways","volume":"273","author":"De Cesaris","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2023.110806_b0270","doi-asserted-by":"crossref","first-page":"135","DOI":"10.59566\/IJBS.2010.6135","article-title":"IL-6 Induction by TNF\u03b1 and IL-1\u03b2 in an Osteoblast-Like Cell Line","volume":"6","author":"Confalone","year":"2010","journal-title":"Int. J. Biomed. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2023.110806_b0275","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4049\/jimmunol.1301836","article-title":"Human Th2 but not Th9 cells release IL-31 in a STAT6\/NF-\u03baB-dependent way","volume":"193","author":"Maier","year":"2014","journal-title":"J. Immunol.(Baltimore, Md, 1950)"},{"key":"10.1016\/j.intimp.2023.110806_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01383","article-title":"Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases","volume":"10","author":"Gibbs","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110806_b0285","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923011311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923011311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:37:29Z","timestamp":1736433449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923011311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":57,"alternative-id":["S1567576923011311"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110806","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of infliximab for pruritus in mice model of cholestasis induced by bile duct ligation: Possible involvement of IL-31","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110806"}}